Ehrlichia canis DIVA Diagnostic Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately differentiate between animals naturally infected with Ehrlichia canis and those vaccinated against the pathogen, which is crucial for effective disease management and diagnosis.
Innovation Solution
A method involving the use of specific Ehrlichia canis polypeptides, where antibodies from an animal are tested for binding to both a polypeptide not part of the vaccine and one that is, to determine infection status, utilizing techniques like radioimmunoassay or enzyme-linked immunosorbent assay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used to detect E. canis infection, then infection detection is performed, but vaccinated animals cannot be differentiated from naturally infected animals
Solution Approach 1:
The diagnostic approach is segmented into two separate detection components: one targeting vaccine-specific antigens and another targeting natural infection-specific antigens. This segmentation allows the diagnostic system to distinguish between vaccinated and naturally infected animals by detecting which specific antigen-antibody interactions are present, thereby resolving the inability to differentiate infection status.
Solution Approach 2:
Specific polypeptides serve as intermediaries that bridge the detection gap. These polypeptides are selected to be present in natural infections but absent in vaccinated animals, acting as mediators that enable differentiation. The polypeptides include specific outer membrane proteins and other infection-specific markers that do not cross-react with vaccine components.
2Ease of operation
If a single polypeptide detection method is used, then the diagnostic process is simple, but it cannot distinguish between vaccine-induced and infection-induced antibodies
Solution Approach 1:
The diagnostic method merges multiple detection capabilities into a single integrated assay system. By combining detection of both vaccine-specific and infection-specific polypeptides in one diagnostic procedure, the system maintains operational simplicity while achieving precise differentiation. The merged approach uses a panel of polypeptides that can be tested simultaneously in a single sample analysis.
3Reliability
If polypeptides that are elements of the vaccine are used for detection, then vaccinated animals show positive results, but naturally infected animals cannot be reliably identified
Solution Approach 1:
The diagnostic system applies local quality by selecting specific polypeptides with distinct presence patterns. Vaccine polypeptides are identified as having high concentration in vaccinated animals, while infection-specific polypeptides (including certain outer membrane proteins) are identified as having high concentration only in naturally infected animals. This local quality differentiation enables reliable status identification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise differentiation between infected and vaccinated animals, enabling early detection and appropriate treatment of Ehrlichia canis infections.
Implementation Method 1
detecting whether antibodies in the sample specifically bind to the first and the second purified E. canis polypeptides
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to Ehrlichia canis antigens that can be used to differentiate E. canis infected animals from animals that have been challenged with E. canis, e.g. vaccinated against E. canis.